Igen bioterror defense
This article was originally published in The Gray Sheet
Origen biothreat environmental detection product contract with Department of Defense's Joint Program Executive Office for Chemical & Biological Defense will bring in $23 mil. over four years and double the firm's biodefense revenues over the next year, Igen says. During FDA's April Science Forum, PEO-CBD said its initial protocol likely would be a Roche Taqman PCR-type device (1"The Gray Sheet" May 5, 2003, p. 10)...
You may also be interested in...
The diagnostic platform targeted by the Department of Defense's bioterrorism acquisition process likely will include electrochemiluminescence (ECL) technology, according to DoD
The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.